Conoa-B (02162) rose more than 6%. As of press release, it had risen 6.17% to HK$30.95, with a turnover of HK$8.98,800.
The Zhitong Finance App learned that Conoa-B (02162) rose more than 6%. As of press release, it had risen 6.17% to HK$30.95, with a turnover of HK$8.9888 million.
According to the news, Conoa-B announced that its non-wholly-owned subsidiary KYM, with the biopharmaceutical company AstraZeneca (AZN.US), signed an exclusive global license agreement in February to develop and commercialize the company's pipeline product CMG901 (AZD0901). Up to now, AstraZeneca has conducted multiple clinical studies on CMG901 (AZD0901) for the treatment of advanced solid tumors.
Changjiang Securities released a research report saying that the company's core product, CM310, has submitted a listing application, and the indications continue to expand, opening up a growth ceiling. CM310 is the fastest progressing IL-4Rα monoclonal antibody developed by the company. Phase III clinical trial studies for moderate to severe atopic dermatitis (AD) in adults have been completed in 2023. In addition, CM310 launched two phase III clinical studies on moderate to severe AD and seasonal allergic rhinitis in adolescents in China in 2023, which is expected to further expand the future market potential of the product.
According to the report, the company's product CMG901 read PFS data, showing potential for later-line G/GEJ treatment. Previously, CMG901 (Claudin18.2-adc) for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma (G/GEJ) was approved by the FDA as an orphan drug and fast track. At the same time, it was granted breakthrough therapy certification by the CDE in China, and the product value was fully revealed. AstraZeneca has conducted a number of international multi-center clinical studies on CMG901/AZD0901 for the treatment of advanced solid tumors, further enhancing the commercial potential of the product.